What this trial studies
Gonal-F® (follitropin alfa) is a recombinant FSH without LH activity, while Menopur® contains both LH and hCG. The MEGASET trial compared Menopur® and Gonal-F® in GnRH antagonist cycles with SET, showing similar efficacy. A subsequent study (MEGASET-HR) in high responders found ongoing pregnancy rates of 35.5% for Menopur® and 30.7% for Gonal-F®, with a lower early pregnancy loss for Menopur® (14.5% vs 25.5%). Telomere length (TL) in oocyte cumulus cells (CC) correlates with oocyte quality and embryo outcomes.
Conditions in scope
- OVARIAN STIMULATION
- Telomere Length
- Telomere Length, Mean Leukocyte
Interventions
- Not specified in the public record.
Who can join
Women only · Ages 18 Years to 38 Years · Accepts healthy volunteers.
Inclusion criteria
- Maternal age 18 - 38 years
- Patients requested PGT-A
- BMI 18- 30kg/m2
- Expected normoresponders
- Fresh autologous ejaculate (≥5 mill/ml)
- Sperm abstinence: 2-3 days
- Normal female/male karyotype
- Regular menstrual cycle length: 25-32 days
Exclusion criteria
- \. Uterine abnormalities as diagnosed by ultrasound 2. Any hormonal or oral contraceptive pretreatment of 3 months preceding the treatment 3. Endometriosis according to American Fertility Society (AFS) ≥3 4. ≥ 2 miscarriages 5. Bologna criteria poor responders (14)
Eligibility wording paraphrased from the public record. View the full criteria on ClinicalTrials.gov before contacting a site.
Where it’s happening
| City | State / Region | Facility | Site status |
|---|---|---|---|
| Abu Dhabi | Abu Dhabi Emirate | ART Fertility Clinics | Recruiting |
Status & timeline
- Overall status: Recruiting
- Study type: Observational
- Phase: N/A
- Start date: 2025-07-23
- Primary completion: 2026-12-31
- Last update posted: 2025-07-25
- First posted: 2024-12-13
Sponsor & contact
Lead sponsor: ART Fertility Clinics LLC (Other)
Collaborators: Merck Sharp & Dohme LLC
For trial site contact information, use the official record at ClinicalTrials.gov. Contact details change frequently and the public record is the source of truth.
Outcome measures
Primary outcomes
- In this study the investigators will investigate the telomere length of cumulus cells between two stimulation cycles, using different stimulation medication (rFSH versus hMG) within same patient/woman (12 weeks)
In this study the investigators will investigate the telomere length of cumulus cells between two stimulation cycles, using different stimulation medication (rFSH versus hMG) within same patient/woman
Related ClearedRx care
If you’re reading this trial because you have menopause symptoms now, you don’t have to wait for a trial to access evidence-based care. ClearedRx prescribes the same FDA-approved and compounded HRT products that have been studied in trials like this one for decades.
Important. Information from ClinicalTrials.gov as of May 8, 2026. Trial details (status, sites, contacts, eligibility, outcomes) change frequently — always check the official record at https://clinicaltrials.gov/study/NCT06732843 before contacting a site.
ClearedRx is not affiliated with this trial or its sponsor. We index public-domain ClinicalTrials.gov records to help patients find evidence-based context for menopause care decisions. ClearedRx itself is a telehealth menopause/HRT brand — we do not enroll patients in trials.